Paul L. Nguyen, MD, on Prostate Cancer: High-Risk Disease, Brachytherapy, And Hormones
2016 ASTRO Annual Meeting
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)
Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)
Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.
Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)
Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostate cancer. (Plenary Lecture 1, Presentation 7)
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)